PPLPHARMAPharmaceuticals
Piramal Pharma Ltd — Cash Flow Statement
₹136.54
+1.77%
Piramal Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 227.92 Cr | 292.50 Cr | -480.86 Cr | -123.09 Cr | — |
| Repayment Of Debt | -1.06K Cr | -861.30 Cr | -3.19K Cr | -1.23K Cr | — |
| Issuance Of Debt | 254.63 Cr | 240.13 Cr | 4.38K Cr | 2.25K Cr | — |
| Issuance Of Capital Stock | 0.00 | 1.05K Cr | 0.00 | -0.10 Cr | — |
| Capital Expenditure | -664.38 Cr | -712.04 Cr | -964.75 Cr | -889.51 Cr | — |
| End Cash Position | 182.32 Cr | 219.19 Cr | 53.23 Cr | 85.18 Cr | — |
| Beginning Cash Position | 219.19 Cr | 53.23 Cr | 85.18 Cr | 261.97 Cr | — |
| Effect Of Exchange Rate Changes | -10.88 Cr | 17.79 Cr | 5.15 Cr | -2.04 Cr | — |
| Changes In Cash | -25.99 Cr | 148.19 Cr | -37.10 Cr | -251.49 Cr | — |
| Financing Cash Flow | -440.83 Cr | -422.34 Cr | 817.79 Cr | 794.19 Cr | — |
| Net Other Financing Charges | 0.01 Cr | 0.02 Cr | — | — | 100.85 Cr |
| Interest Paid Cff | -447.38 Cr | -469.61 Cr | -278.12 Cr | -144.51 Cr | — |
| Cash Dividends Paid | -14.47 Cr | — | -67.00 Cr | -50.00 Cr | — |
| Common Stock Dividend Paid | -14.47 Cr | 0.00 | -67.00 Cr | -50.00 Cr | — |
| Net Common Stock Issuance | 0.00 | 1.05K Cr | 0.00 | -0.10 Cr | — |
| Common Stock Issuance | 0.00 | 1.05K Cr | 0.00 | -0.10 Cr | — |
| Net Issuance Payments Of Debt | 48.71 Cr | -971.53 Cr | 1.20K Cr | 1.02K Cr | — |
| Net Short Term Debt Issuance | 858.59 Cr | -350.36 Cr | 357.14 Cr | 353.25 Cr | — |
| Net Long Term Debt Issuance | -809.88 Cr | -621.17 Cr | 841.28 Cr | 665.88 Cr | — |
| Long Term Debt Payments | -1.06K Cr | -861.30 Cr | -1.72K Cr | -237.95 Cr | — |
| Long Term Debt Issuance | 254.63 Cr | 240.13 Cr | 2.56K Cr | 903.83 Cr | — |
| Investing Cash Flow | -477.46 Cr | -434.01 Cr | -1.34K Cr | -1.81K Cr | — |
| Net Other Investing Changes | 16.30 Cr | -4.25 Cr | -73.31 Cr | -0.01 Cr | — |
| Dividends Received Cfi | 46.31 Cr | 22.05 Cr | 75.41 Cr | 81.59 Cr | — |
| Net Investment Purchase And Sale | 119.06 Cr | 258.63 Cr | -375.47 Cr | -130.83 Cr | — |
| Sale Of Investment | 2.00K Cr | 1.95K Cr | 847.91 Cr | 1.40K Cr | — |
| Purchase Of Investment | -1.89K Cr | -1.69K Cr | -1.22K Cr | -1.53K Cr | — |
| Net PPE Purchase And Sale | -659.13 Cr | -710.44 Cr | -945.06 Cr | -857.09 Cr | — |
| Sale Of PPE | 5.25 Cr | 1.60 Cr | 19.69 Cr | 32.42 Cr | — |
| Purchase Of PPE | -664.38 Cr | -712.04 Cr | -964.75 Cr | -889.51 Cr | — |
| Operating Cash Flow | 892.30 Cr | 1.00K Cr | 483.89 Cr | 766.42 Cr | — |
| Taxes Refund Paid | -334.36 Cr | -156.84 Cr | -189.00 Cr | -169.42 Cr | — |
| Change In Working Capital | -487.72 Cr | -234.30 Cr | -302.08 Cr | -292.29 Cr | — |
| Change In Other Current Liabilities | -12.77 Cr | 230.67 Cr | 19.97 Cr | 64.32 Cr | — |
| Change In Other Current Assets | -69.97 Cr | 42.70 Cr | 30.14 Cr | -81.39 Cr | — |
| Change In Payable | 18.24 Cr | 404.30 Cr | -271.65 Cr | 79.12 Cr | — |
| Change In Inventory | -197.12 Cr | -531.75 Cr | -172.64 Cr | -175.64 Cr | — |
| Change In Receivables | -233.45 Cr | -391.39 Cr | 89.26 Cr | -185.17 Cr | — |
| Other Non Cash Items | 368.06 Cr | 436.45 Cr | 303.34 Cr | 158.04 Cr | — |
| Stock Based Compensation | 48.00 Cr | 27.47 Cr | 0.00 | — | — |
| Provisionand Write Offof Assets | 8.70 Cr | -15.05 Cr | -6.95 Cr | -52.69 Cr | — |
| Depreciation And Amortization | 816.34 Cr | 740.56 Cr | 676.69 Cr | 586.18 Cr | — |
| Depreciation | 816.34 Cr | 740.56 Cr | 676.69 Cr | 586.18 Cr | — |
| Gain Loss On Investment Securities | -9.05 Cr | 0.48 Cr | -2.56 Cr | -23.13 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 31.60 Cr | 48.28 Cr | 71.56 Cr | 72.98 Cr | — |
| Gain Loss On Sale Of PPE | -1.44 Cr | 0.46 Cr | 0.48 Cr | 0.54 Cr | — |
| Net Income From Continuing Operations | 341.71 Cr | 119.80 Cr | -160.56 Cr | 441.03 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -0.02 Cr | — | 76.74 Cr | — |
| Short Term Debt Payments | — | -1.77K Cr | -1.46K Cr | -996.47 Cr | -383.01 Cr |
| Short Term Debt Issuance | — | 1.42K Cr | 1.82K Cr | 1.35K Cr | 473.39 Cr |
| Net Business Purchase And Sale | — | 0.00 | -20.35 Cr | -906.45 Cr | -3.78K Cr |
| Purchase Of Business | — | 0.00 | -20.35 Cr | -906.45 Cr | -3.78K Cr |
| Interest Received Cfi | — | — | 0.00 | 0.68 Cr | 0.49 Cr |
| Net Preferred Stock Issuance | — | — | — | 0.00 | 75.00 Cr |
| Preferred Stock Issuance | — | — | — | 0.00 | 75.00 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Piramal Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.